DenyerJ, DycheT. The Adaptive Aerosol Delivery (AAD) technology: past, present and future. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-1–S-10.
2.
HardakerLEA, HatleyRHM. In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) System. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-11–S-20.
3.
NikanderK, DenyerJ, DoddM, DycheT, WebbK, WellerP, StableforthD. The Adaptive Aerosol Delivery System in a telehealth setting: patient acceptance, performance, and feasibility. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-21–S-27.
4.
NikanderK, PrinceI, CoughlinS, WarrenS, TaylorG. Mode of breathing—Tidal or slow and deep—through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-37–S-43.
5.
DenyerJ, PrinceI, DixonE, AgentP, PryorJ, HodsonM. Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-29–S-36.
6.
DenyerJ, BlackA, NikanderK, DycheT, PrinceI. Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-45–S-54.
7.
GellerDE, KesserKC. The I-neb Adaptive Aerosol Delivery System enhances aerosol delivery of α1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-55–S-59.
8.
GoodmanN, MorganM, NikanderK, HinchS, CoughlinS. Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Del, 2010; 23,Suppl 1:S-61–S-70.
9.
RauJL. Design principles of liquid nebulization devices currently in use. Respir Care, 2002; 47:1257–1275.
10.
DhandR. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care, 2002; 47:1406–1416.
11.
Van DykeR, NikanderK. Delivery of iloprost inhalation solution with HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery (AAD) systems—an in vitro study. Respir Care, 2007; 53:184–190.
12.
DhandR, GiriVV, NothI, LissinD, FishmanRS, TaylorK. Bronchodilator response to ipratropium delivered via Aerodose inhaler or Pari LC Plus nebulizer in COPD. Am J Respir Crit Care Med, 2002; 165:A593.
13.
NewmanSP, PaviaD, GarlandN, ClarkeSW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis, 1982; 63,Suppl:57–65.
14.
BennettWD, SmaldoneGC. Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol, 1987; 62:1603–1610.
15.
BrandP, SchulteM, WenckerM, HerpichCH, KleinG, HannaK, MeyerT. Lung deposition of inhaled alpha 1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J, 2009; 34:354–360.
16.
SanderN, Fusco-WalkertSJ, HarderJM, ChippsBE. Dose counting and the use of pressurized metered-dose inhalers: running on empty. J Allergy Asthma Immunol, 2006; 97:34–38.
17.
McNamaraP, McCormackP, McDonaldAJ, HeafL, SouthernKW. Open adherence monitoring using data download from an adaptive aerosol delivery nebulizer in children with cystic fibrosis. J Cystic Fibrosis, 2009; 8:258–263.
